CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas.

Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.

Paclitaxel is under clinical development by InnoUp Farma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

MET-3 is under development for the treatment of hypertriglyceridemia. It comprises live microbiota that normally reside in the human gut of a healthy individual. It is administered through oral route ...

BG-102 is under clinical development by SL Bigen and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...

MOMA-313 is under development for the treatment of solid tumors including metastatic breast cancer, metastatic pancreatic cancer, metastatic prostate cancer. It acts by targeting DNA polymerase theta.

HRS-1167 is under clinical development by Merck and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC).

MOMA-313 is under clinical development by Moma Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer.

BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase II for Epithelial Ovarian Cancer.

Bivamelagon is under clinical development by Rhythm Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate ...

GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Rheumatoid Arthritis.

Coronavirus Disease 2019 (SARS-CoV-2) vaccine is under clinical development by Shionogi and currently in Phase III for Coronavirus Disease 2019 (COVID-19).